BIO vs IMUX · rev $651.0M vs $79.5M cap
BIO (BIO) versus Immunic Inc (IMUX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Immunic Inc (IMUX) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
IMUX does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. IMUX currently screens at market cap $79.5M.
Not investment advice. Open the BIO and IMUX stock pages for the full models.
Not investment advice.